Absorption, distribution, metabolism and elimination of 14C-ETX0914, a novel inhibitor of bacterial type-II topoisomerases in rodents

scientific article published on 28 April 2016

Absorption, distribution, metabolism and elimination of 14C-ETX0914, a novel inhibitor of bacterial type-II topoisomerases in rodents is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3109/00498254.2016.1156186
P698PubMed publication ID27122100

P2093author name stringJian Guo
Gregory S Basarab
Camil Joubran
Karthick Vishwanathan
Ricardo A Luzietti
Scott W Grimm
P2860cites workEmerging mechanisms of fluoroquinolone resistanceQ24644842
Structure and mechanism of DNA topoisomerase IIQ27732221
Exploiting bacterial DNA gyrase as a drug target: current state and perspectives.Q34214929
In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groupsQ35758905
A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering systemQ35821755
Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.Q35848139
Global fluoroquinolone resistance epidemiology and implictions for clinical use.Q36337074
Pregnenolone 16 alpha-carbonitrile-inducible P-450 gene family: gene conversion and differential regulationQ36480892
Bacterial DNA replication enzymes as targets for antibacterial drug discoveryQ37998090
Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914).Q38855047
Synthesis of a tetrahydronaphthyridine spiropyrimidinetrione DNA gyrase inhibiting antibacterial agent--differential substitution at all five carbon atoms of pyridineQ41627721
In vitro and in vivo metabolism of 14C-AZ11, a novel inhibitor of bacterial DNA gyrase/type II topoisomeraseQ44147488
Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: A statistical analysis studyQ44439017
Synthesis of (-)-PNU-286607 by asymmetric cyclization of alkylidene barbituratesQ44556801
Fluoroquinolones: mechanisms of action and resistance.Q54249946
P433issue1
P407language of work or nameEnglishQ1860
P304page(s)31-49
P577publication date2016-04-28
P1433published inXenobioticaQ1360678
P1476titleAbsorption, distribution, metabolism and elimination of 14C-ETX0914, a novel inhibitor of bacterial type-II topoisomerases in rodents
P478volume47

Reverse relations

Q58100697Single-dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteerscites workP2860